𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Abbreviated dose rituximab for immune-mediated hematological disorders

✍ Scribed by Helen Fairweather; Annabel Tuckfield; Andrew Grigg

Book ID
101434514
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
96 KB
Volume
83
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Rituximab for refractory Evans syndrome
Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases
✍ Elpis Mantadakis; Vassiliki Danilatou; Eftichia Stiakaki; Maria Kalmanti πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 104 KB

## Abstract The authors describe a 21‐year‐old man with long‐lasting Evans syndrome refractory to corticosteroids and immunosuppressive agents; the patient responded to four weekly infusions of rituximab. The patient relapsed with thrombocytopenia 7 months post‐therapy and was successfully re‐treat

Rituximab therapy for thrombotic thrombo
Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders
✍ James N. George; Robert D. Woodson; Joseph E. Kiss; Kiarash Kojouri; Sara K. Ves πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 101 KB

## Abstract The rationale for immunosuppressive therapy of thrombotic thrombocytopenic purpura (TTP) was established by observations that TTP may be caused by autoantibodies to ADAMTS13. Patients with high‐titer autoantibodies to ADAMTS13 may have a higher mortality, and survivors may require prolo